A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment With Tiotropium 18 Mcg Capsule Once Daily in Patients With COPD in a Veterans Affairs Setting
- NCT00274547
- PHASE3
- INTERVENTIONAL
Last updated: 2013-11-01
Purpose of Trial
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observation period.
This study is for people with
Pulmonary Disease, Chronic Obstructive
Interventions being studied
Tiotropium
ELIGIBILITY
Gender: ALL
Age: 40+
Healthy Volunteers: No
26 Locations
Birmingham
Boehringer Ingelheim Investigational Site
Alabama, United States
Phoenix
Carl T. Hayden VA Medical Center
Arizona, United States
Tuscon
Southern Arizona VA Health Care System
Arizona, United States
Long Beach
VA Long Beach Healthcare System
California, United States
Palo Alto
Boehringer Ingelheim Investigational Site
California, United States
Bay Pines
Respiratory Diseases (111A)
Florida, United States
Gainesville
J. Hillis Miller Health Center
Florida, United States
Hines
Veteran Affairs Medical Center
Illinois, United States
North Chicago
Veterans Affairs Medical Center
Illinois, United States
Indianapolis
Boehringer Ingelheim Investigational Site
Indiana, United States
Lexington
Boehringer Ingelheim Investigational Site
Kentucky, United States
Metairie
4720 I-10 Service Road
Louisiana, United States
Boston
Boehringer Ingelheim Investigational Site
Massachusetts, United States
Minneapolis
Veteran Affairs Medical Center
Minnesota, United States
Kansas City
Boehringer Ingelheim Investigational Site
Missouri, United States
Omaha
Boehringer Ingelheim Investigational Site
Nebraska, United States
Reno
Boehringer Ingelheim Investigational Site
Nevada, United States
Buffalo
Boehringer Ingelheim Investigational Site
New York, United States
New York
Bronx VA Medical Center
New York, United States
Durham
Boehringer Ingelheim Investigational Site
North Carolina, United States
Dallas
Dallas VAMC
Texas, United States
Houston
Veterans Affairs Medical Center
Texas, United States
San Antonio
Boehringer Ingelheim Investigational Site
Texas, United States
Salt Lake City
Boehringer Ingelheim Investigational Site
Utah, United States
Hampton
Hampton VA Medical Center
Virginia, United States
Richmond
Hunter Holmes McGuire Medical Center
Virginia, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov
